Polls generally show that the majority of Americans are on board with the death penalty. In October 2014, Gallup reported that 63 percent of Americans were in favor of capital punishment while 33 percent were opposed.
House Republicans quietly deepened recommended budget savings from the government's chief health care program for the poor by about $140 billion in recent weeks to offset part of the cost of higher payments to doctors who treat Medicare patients, according to officials familiar with the tradeoff.
Gilead Sciences Canada today announced that multiple provinces will provide public access to Harvoni ™ (ledipasvir/sofosbuvir), the first once-daily, single tablet regimen for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults.
BMS Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune DiseasesMarch 24, 2015 8:16 am | News | Comments
Bristol-Myers Squibb Company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.
Advanced development is underway on an improved anthrax vaccine that could provide protection in fewer doses than the currently licensed anthrax vaccine and so may be more cost-effective to stockpile.
The agency said its tracking of claims by cosmetics companies during recent years indicated a proliferation in drugs claims--defined by the FDA as "intended to treat or prevent disease, or change the body’s structure or functions"--on product packaging and in web advertising.
The HFX205 Formaldehyde Monitor designed for use in a wide variety of applications such as furniture, floorboards, wallpapers, paint, gardening, indoor decorations, construction, dye stuffs, paper manufacture, pharmaceutical, medical, food, cleaning, synthetic resins, textile treatment, horticulture and cosmetics.
While most architecture in the world is devoted to creating environments for human occupancy, who is tasked with designing facilities that manufacture drug products to occupy humans?
In recent years, new technology has provided a number of significant improvements to aseptic processing facilities.
The World Health Organization denied that politics swayed the decision to declare an international emergency over the spread of the Ebola virus last year, despite evidence senior staffers repeatedly discussed the diplomatic and economic fallout of such a move.
Takeda will use ImmunoGen's technology to develop cancer treatments. ImmunoGen will get $20 million upfront and is eligible for milestone payments potentially totaling up to $210 million, plus royalties on sales.
Teva Pharmaceutical Industries has announced the appointment of Timothy R. Wright to the Company’s executive leadership team, heading business development, strategy and innovation.
Calling the federal agency that oversees vaccines a "sock puppet" for that industry, Robert Kennedy Jr. spoke out Monday in favor of allowing parents to choose whether to vaccinate their children.
The past several years have witnessed a significant increase in the rate of adoption for single use disposable systems for aseptic fill/finish applications. Paralleling recent advances in flexible aseptic filling lines, single-use disposable systems (SUDS) for aseptic fill/finish facilities promise increased flexibility and streamlined operations.
Liberians are overcoming their fears of Ebola to volunteer for a vaccine trial.